Assignee
CYTODYN INC
US·5 granted patents·10 pending applications·39 citations·filing 2012–2021
Top patents by PatentIndex Score
15 records- 0191US11045546B1Methods of treating coronavirus infectionCYTODYN INC·Filed 2020·Granted Jun 29, 2021·39 cites·19 claims
- 0268US2014377259A1Methods for inhibiting hiv-1 replication involving the administration of an anti-ccr5 receptor monoclonal antibody and small molecule ccr5 receptor antagonistCYTODYN INC·Filed 2014·Application pending·0 cites
- 0363US2020306372A1Methods for reducing viral load in hiv-1 infected patientsCYTODYN INC·Filed 2019·Application pending·0 cites
- 0457US10500274B2Methods for reducing viral load in HIV-1 infected patientsCYTODYN INC·Filed 2012·Granted Dec 10, 2019·0 cites·12 claims
- 0555US11571383B2Concentrated protein formulations and uses thereofCYTODYN INC·Filed 2018·Granted Feb 7, 2023·0 cites·19 claims
- 0653US2021214448A1Ccr5 binding agent for the treatment of ccr5 positive metastatic cancerCYTODYN INC·Filed 2021·Application pending·0 cites
- 0748US2022298249A1Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agentsCYTODYN INC·Filed 2020·Application pending·0 cites
- 0844US2022162327A1Anti-ccr5 agents and methods of treatment that block cancer metastasis or enhance cell death induced by dna damaging chemotherapyCYTODYN INC·Filed 2020·Application pending·0 cites
- 0941US2020385475A1Substitution monotherapy treatment for hiv-1 infection employing antibody pro140CYTODYN INC·Filed 2020·Application pending·0 cites
- 1040US2019085086A1Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapyCYTODYN INC·Filed 2018·Application pending·0 cites
- 1140US2019016810A1Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agentsCYTODYN INC·Filed 2018·Application pending·0 cites
- 1237US2019014758A1Humanized mouse modelCYTODYN INC·Filed 2018·Application pending·0 cites
- 1332US11584797B2Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditionsCYTODYN INC·Filed 2016·Granted Feb 21, 2023·0 cites·11 claims
- 1431US10562969B2Substitution monotherapy treatment for HIV-1 infection employing antibody PRO140CYTODYN INC·Filed 2015·Granted Feb 18, 2020·0 cites·13 claims
- 1524US2017049884A1Use of anti-ccr5 antibodies in graft versus host diseaseCYTODYN INC·Filed 2015·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →